Prognostic benefit of surgery following chemoradiotherapy for squamous cell carcinoma of the oesophagus  by McGlone, Emma R. & Khan, Omar A.
at SciVerse ScienceDirect
International Journal of Surgery 10 (2012) 341e344
REVIEWContents lists availableInternational Journal of Surgery
journal homepage: www.thei js .comReview
Prognostic beneﬁt of surgery following chemoradiotherapy for squamous cell
carcinoma of the oesophagus
Emma R. McGlone a, Omar A. Khan b,*
aDepartment of Surgery, Queen Alexandra Hospital, Cosham, Portsmouth PO6 3LY, UK
bDepartment of Upper GI Surgery, St. George’s Hospital, London, UKa r t i c l e i n f o
Article history:
Received 31 July 2011
Received in revised form
15 May 2012
Accepted 20 May 2012
Available online 25 May 2012
Keywords:
Oesophageal cancer
Chemoradiotherapy* Corresponding author. Tel./fax: þ44 2392286000
E-mail address: okhan342@gmail.com (O.A. Khan)
1743-9191/$ e see front matter  2012 Surgical Asso
doi:10.1016/j.ijsu.2012.05.008a b s t r a c t
A best evidence topic in surgery was written according to a structured protocol. The question addressed
was whether patients who have undergone chemoradiotherapy (CRT) for locally advanced squamous cell
carcinoma of the oesophagus beneﬁt from surgical resection. 505 papers were found using the reported
search, of which 5 represented the best evidence to answer the clinical question. The authors, journal,
date and country of publication, patient group, study type, relevant outcomes and results of these papers
are tabulated. Of these ﬁve studies, two were randomised controlled trials. These demonstrated that
there was no survival beneﬁt in adding surgery to patients who have undergone CRT for oesophageal
cancer. The remaining three observational studies suggest that surgery may have a prognostic beneﬁt for
patients who show a partial, but not complete response to CRT. We conclude that for patients who are
complete responders to induction CRT, surgery adds no survival beneﬁt. With regard to partial
responders there is weak evidence suggesting that there may be some beneﬁt in surgery after CRT, but
further trials are needed to clarify the survival beneﬁt (if any) of adding oesophagectomy to CRT for this
sub-group.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Although surgery has traditionally been the mainstay of
successful treatment for oesophageal cancers, recent advances in
other treatment modalities have challenged the primacy of
surgical resection. Following the publication of the MRC study2
the standard practice in the UK is to offer chemotherapy prior
to surgery for all resectable oesophageal cancer. With respect to
upper and mid-oesophageal tumours, in addition to chemo-
therapy, radiotherapy has also been shown have a role in local
tumour control and as a consequence of this ﬁnding, a number of
studies have examined the impact of combining chemotherapy
and radiotherapy in the treatment of these cancers.3 Although
deﬁnitive chemoradiotherapy (CRT) has been usually reserved for
patients considered unsuitable for surgery, with ongoing
advances in the effectiveness of CRT regimens, debate now
centres on the need for oesophagectomy at all following CRT in
those patients with locally-advanced but operable tumours that
have responded to chemoradiation. Some argue that the high rate
of local recurrence after primary chemoradiotherapy makes.
.
ciates Ltd. Published by Elsevier Ltsurgery necessary; others point out that surgery entails high
morbidity and since the majority of those with locally advanced
cancers develop metastatic disease, it is unlikely to improve
overall prognosis. There are no systematic reviews or meta-
analyses in the literature to which to refer when deciding
whether or not to follow successful CRT with surgical resection.
Since this question is both clinically relevant and remains unan-
swered by high level studies, a Best Evidence Topic (Best BET) was
constructed to provide readers with a robust and easily-accessible
summary of the evidence so far. This approach is a structured and
validated way of collecting and assessing the best available
evidence to answer a clinical question.12. Clinical scenario
You are at a MDT discussing a patient with locally advanced
squamous cell oesophageal cancer, who has undergone a course of
chemoradiotherapy. His repeat imaging shows a good response to
induction therapy. Although the patient has good performance
status and there are no contraindications to surgery, the oncologist
suggests that there is no survival beneﬁt to proceeding with
surgery. You resolve to check the literature to determinewhether ord. All rights reserved.
Table 1
Best Evidence Papers.
Author, date and country Patient group (CRT ¼
chemoradiotherapy
S ¼ surgery)
Study type and
level of evidence
Outcomes Key results Comments
Bedenne et al. (2007),
France Level II
Prospective,
randomised
controlled trial4
259 patients with
squamous cell carcinoma
or adenocarcinoma of
the oesophagus, T3 N0-1
M0, who had responded
to induction CRT.
CRT þ S n ¼ 129
CRT alone n ¼ 130
Level II Prospective,
randomised
controlled
trial
Survival
(CRT þ S vs.
CRT alone)
Median survival:
17.7 months vs. 19.3 months
(no signiﬁcant difference)
Overall survival at 2 years:
34% vs. 40%: (no signiﬁcant
difference)
This study examined
both complete and partial
responders to induction CRT,
but excluded non-responders.
It failed to show any difference
in overall or median survival
between the two groups.
There was some heterogeneity
in the cohort as it included
patients with both squamous
and adenocarcinomas.
In addition there was no
standardised pre-operative
staging, radiotherapy regimens
or surgical technique
Other outcomes
(CRT þ S vs.
CRT alone)
Mean length of hospital stay:
38.6 days vs. 24.7 days:
(p < 0.0001)
Number requiring procedure
for dysphagia following
therapy: 24% vs. 46%:
(p < 0.001)
Quality of life: no difference
after ﬁrst 6 months.
6-month mortality rate:
16% vs. 6%: (p ¼ 0.015)
Stahl et al. (2005),5
Germany
172 patients with
histologically proven
squamous cell carcinoma
of upper or mid third
oesophagus,
T3-4 N0-1 M0.
CRT þ S n ¼ 86
CRT alone n ¼ 86
Level II Prospective,
randomised
controlled
trial
Survival
(CRT þ S vs.
CRT alone)
Median survival:
16.4 months vs.
14.9 months (no signiﬁcant
difference)
Overall survival at 2 years:
39.9% vs. 35.4%:
(no signiﬁcant difference)
This study failed to show
any difference in overall or
median survival between the
two groups. It should be noted
that patients who were
non-responders to induction
CRT were included in this
study. In addition, patients
who did not have surgery
had dose escalation of
radiotherapy.
Treatment related
mortality:
CRT þ S vs. CRT
alone)
Treatment related mortality:
12.8% vs. 3.5%: (p ¼ 0.03)
2 year local progression free
survival: 64.3% vs. 40.7%:
(p ¼ 0.003)
Other ﬁndings: Clinical response to induction
CRT was independent prognostic
factor for overall survival
(p < 0.0001)
Liao et al. May 20046
China
68 patients with T3-4
N0-1 M0
oesophageal cancer,
with matched performance
status, tumour stage and
tumour location in the two
groups
CRT þ S n ¼ 34
CRT alone n ¼ 34.
Level III
Retrospective
matched
cohort
study
Survival
(CRT þ S vs. CRT
alone)
2-year overall survival:
62% vs. 21%:
(p < 0.0001)
This study retrospectively
analysed 132 consecutive
patients with non-randomised
management and conducted
a sub-group analysis of
patients with CRT þ S and
CRT alone.
The CRT regimens and
surgical techniques were
not standardised, however the
results suggest a survival
beneﬁt for patients treated
with surgery as a consequence
of improved local control.
Other outcomes
(CRT þ S vs. CRT
alone)
2-year loco-regional control
rate: 80.2% vs. 17.1%:
(p < 0.0001)
2-year disease-free survival:
64.0% vs. 24.3%:
(p < 0.0001)
Distant metastasis free
survival (time from diagnosis
date to ﬁrst evidence of distant
metastases): 68.7% vs. 65.1%
(not signiﬁcant)
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Table 1 (continued )
Author, date and country Patient group (CRT ¼
chemoradiotherapy
S ¼ surgery)
Study type and
level of evidence
Outcomes Key results Comments
Hennequin
et al. (2001)7
France
112 patients with locally
advanced oesophageal
cancer
CRT þ S n ¼ 38
CRT alone n ¼ 62
Level IV
Retrospective,
non-randomised
study
Survival (CRT þ S
vs. CRT alone)
1- and 5-year survival rates:
75.4% and 40% vs. 48% and
25.7% (p ¼ 0.0034)
This retrospective analysis
suggested that partial
responders do better after
surgery vs. CRT alone whereas
complete responders have
equivalent outcome. The
small size of the cohort and
the non-standardised nature
of the CRT limit the validity
of this conclusion.
Other outcomes
(CRT þ S vs. CRT
alone)
Local control rate:
81.6% vs. 43.2%
Other ﬁndings Response to CRT, performance
status, and surgery all
independent predictors of survival.
Partial (but not complete)
responders have improved
survival after CRT þ S vs.
CRT alone (p ¼ 0.003)
Fujita et al. (2005)8
Japan
53 patients with T4 SCC
in the thoracic oesophagus,
without distant metastases.
CRT þ S n ¼ 30
CRT alone n ¼ 23
Level III Prospective,
non-randomised
Survival (CRT þ
S vs. CRT alone)
Mean 1-, 3- and 5-year
survival rates : 73%, 28%
and 17% vs. 44%, 13%, 13%
(p ¼ 0.08)
This small study allowed
patients to choose whether
to have surgery or not
following CRT severely
limiting the conclusion
which can be drawn. The
study did however indicate
that surgery has more
important role in non-
responders to induction CRT.
Other ﬁndings Among responders to
induction CRT, 5-year
survival of CRT þ S (n ¼ 19)
vs. CRT alone (n ¼ 13):
23% vs. 23%
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improves survival outcomes.
3. Three-part question
In patients who have undergone chemoradiotherapy for locally
advanced squamous cell carcinoma of the oesophagus, does
subsequent oesophagectomy improve survival outcomes?
4. Search strategy
Medline 1966eApril 2010 using the OVID interface:
(Chemoradiotherapy OR chemoradiation) AND (squamous cell
oesophageal cancer) AND (Esophagectomy OROesophagectomy OR
surgery). In addition, the reference lists of the relevant papers were
searched.
5. Search outcome
505 papers were found using the reported search. From these,
ﬁve papers were identiﬁed as representing the best evidence to
answer this clinical question.
6. Results
Details of the ﬁve papers containing the best available evidence
are summarised in Table 1. All ﬁve papers compare CRT alone with
CRT followed by surgery in the treatment of oesophageal cancer,
with survival as a primary end-point. Two are RCTs with consid-
erable methodological ﬂaws, and three are non-randomised studieswith small numbers of patients. Overall, there is no convincing
evidence that adding surgery to CRT improves survival.
7. Discussion
With neo-adjuvant chemoradiotherapy for patients with
resectable squamous cell oesophageal cancer now offered as
standard across the UK, the management for patients who have
responded to CRT and their need for subsequent resection is
a common topic of discussion and debate in multi-disciplinary
team meetings (MDT) across the country. To date, there have
been two randomised controlled trials that have compared CRT
alone with CRT followed by surgery.4,5 Bedenne et al.4 studied
a total of 259 patients with T3 N0-1 M0 and found that the
addition of surgery gave no beneﬁt in survival outcomes. They
did however ﬁnd that the surgery arm had higher 6-month
mortality and longer hospital stay, but a decreased need for later
palliative procedures for dysphagia. Of their randomised
patients, 89% had squamous cell histology and unfortunately no
subgroup analysis was performed to determine differences
between survival outcomes for squamous cell carcinoma (SCC)
and adenocarcinoma. Since surgery may be the only option for
patients that do not respond to CRT, Bedenne et al.4 excluded
non-responders to induction CRT before randomisation. In
contrast to this study, Stahl et al.5 conducted a randomised trial
which involved only SCC patients but did not exclude non-
responders to induction CRT. This study divided 172 patients
with T3-4 N0-1 M0 randomly into two groups which were treated
with CRT alone or CRT followed by surgery. Overall survival
outcomes were equivalent between the two groups, with the
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suffering higher treatment-related mortality. The authors also
performed a multivariate analysis which showed that tumour
response to induction CRT gives a favourable prognosis,
regardless of subsequent treatment group.
Both the Bedenne and Stahl trials gave additional CRT to the
non-surgical group which introduces major bias into their meth-
odology. In addition the Bedenne trial did not standardise radio-
therapy regimens and neither study used a consistent type of
surgery. These studies nonetheless represent the best quality
evidence available on this topic. Three other observational studies
areworth discussing, however it should be noted that none of these
were randomised and only one was prospective.
As part of a paper reviewing the management of 132 patients
with T3-4 N0-1 M0 oesophageal cancer, Liao et al.6 analysed
a matched cohort study of 68 patients, 34 of whom had received
CRT alone and 34 CRT plus surgery. Unlike the randomised-
controlled trials, this study concluded that survival was better for
patients who had surgery in addition to CRT. The authors however
found no difference in the time from the date of diagnosis to the
ﬁrst evidence of distant metastases and therefore concluded that
the overall survival beneﬁt conferred by surgery was due to
improved local as opposed to systemic control.
Hennequin et al.7 retrospectively examined the management of
112 patients with locally advanced oesophageal cancer who
underwent either CRT alone or CRT and surgery. This group showed
that response to CRT, performance index and surgery were all
independent predictors of survival. Unfortunately as part of their
analysis, they excluded any non-responders to CRT from the dataset
of the surgical group. Hence their ﬁnding of the prognostic beneﬁt
of surgery likely reﬂects the fact that the surgical group was
composed solely of responders to CRT. Of more interest, this study
also found that partial (but not complete) responders to CRT
beneﬁted from the addition of surgery. This ﬁnding was also noted
by Fujita et al.8 who performed a non-randomised study of patients
with T4 cancers. They noted that complete responders to induction
CRT had equal survival outcomes whether or not surgery was
added to CRT; however for partial responders surgery conferred
a survival beneﬁt. However the small numbers and retrospective
nature of both these studies limits strength of this conclusion.
8. Clinical bottom line
Currently the best available evidence suggests that for complete
responders to induction CRT, surgery adds no survival beneﬁt. It
does decrease need for later procedures for dysphagia but is asso-
ciatedwith higher short-termmortality andmorbidity.With regardto partial responders there is weak evidence suggesting that there
may be some beneﬁt in surgery after CRT, but further trials are
needed to clarify whether there is survival beneﬁt of adding
oesophagectomy to CRT for this sub-group. Moreover, since the
above trials did not use standardised regimens of CRT, further
studies are needed to clarify the optimum total dosage that should
be recommended for complete responders to induction CRT.
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